Details:
Zydus received permission to initiate the Phase II (a) clinical study of its NLRP3 inhibitor ZYIL1 for the treatment of Cryopyrin-Associated Periodic Syndrome.
Lead Product(s): ZYIL1
Therapeutic Area: Genetic Disease Product Name: ZYIL1
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021